Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa PA007272.m2a Ushelf

Anti-human CD19 Antibody (Clone: B43) | PA007272.m2a

$200.00 – $1,250.00

Recombinant mouse IgG2a isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.

Details & Specifications
References

Catalog No.	PA007272.m2a
Product Name	In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	B-lymphocyte antigen CD19, Cluster of Differentiation 19, B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12, CVID3
Clone	B43.
Isotype	Mouse IgG2a kappa.
Source/Host	The anti-human CD19 monoclonal antibody (clone: B43) was produced in mammalian cells.
Specificity/Sensitivity	The in vivo grade recombinant mouse monoclonal antibody (clone: B43) specifically binds to the human CD19 protein.
Applications	ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD19 protein.
Form Of Antibody	0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin	< 1 EU per 1 mg of the protein by the LAL method.
Purity	>95% by SDS-PAGE under reducing conditions and HPLC.
Shipping	The In vivo Grade Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
Note	Recombinant mouse IgG2a isotype controls and Recombinant human IgG1 isotype controls are available. Condition of sample preparation and optimal sample dilution should be determined experimentally by the investigator.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007272.m2a: Recombinant Anti-human CD19 Monoclonal Antibody (Clone: B43), Mouse IgG2a Kappa, In vivo Grade

Recombinant mouse IgG2a Monoclonal Antibody.

Background

The B43 antibody binds to the human CD19 protein, a transmembrane protein expressed in all B lineage cells including human plasma cells. CD19 plays two major roles in human B cells: it acts as an adaptor protein to recruit cytoplasmic signaling proteins to the membrane, and works within the CD19/CD21 complex to decrease the threshold for B cell receptor signaling pathways. CD19 is a biomarker for B lymphocyte development, lymphoma diagnosis and can be utilized as a target for leukemia immunotherapies.

References of Anti-human CD19 Monoclonal Antibody (Clone: B43)

1. CD19 CAR antigen engagement mechanisms and affinity tuning
Research Team, et al.Blood Adv. 2023 Jun 13;7(11):2385-2399. doi: 10.1182/bloodadvances.2022009241. PMID: 36749718; PMCID: PMC10228544
“Chimeric antigen receptor (CAR) T-cell therapy targeting CD19 has revolutionized the treatment of B-cell malignancies. This study investigates the biophysical mechanisms of CD19 antigen engagement, focusing on the affinity tuning of therapeutic binders to improve safety and efficacy. By systematically comparing different anti-CD19 clones, the authors demonstrate how modulating binder kinetics can prevent CAR-T cell exhaustion and optimize therapeutic performance.”

2. A high throughput bispecific antibody discovery pipeline
Brunner A, et al.Nat Commun. 2023 Apr 6;14(1):1924. doi: 10.1038/s41467-023-37654-0. PMID: 37024567; PMCID: PMC10082157
“High-throughput screening platforms are essential for identifying therapeutic-grade monoclonal and bispecific antibodies with optimal binding characteristics. This article describes a novel, automated discovery pipeline designed to streamline the isolation of bispecific antibodies targeting complex cell-surface proteins. The utility of this platform is demonstrated through the rapid generation and characterization of functional binders targeting key B-cell markers such as CD19.”

3. A high throughput bispecific antibody discovery pipeline
Brunner A, et al.Nat Commun. 2023 Apr 6;14(1):1924. doi: 10.1038/s41467-023-37654-0. PMID: 37024567; PMCID: PMC10082157
“Developing bispecific antibodies that engage both T cells and tumor antigens requires precise screening of diverse antibody panels to find candidates with optimal therapeutic indexes. Here, the authors present a robust high-throughput pipeline that integrates advanced functional assays with kinetic profiling. This approach successfully identifies high-affinity CD19-targeting arms that can be combined with CD3-binding elements to create highly potent bispecific T-cell engagers.”

4. Getting CD19 Into Shape: Expression of Natively Folded “Difficult-to- Express” CD19 for Staining and Stimulation of CAR-T Cells
Krah S, et al.Front Immunol. 2020 Jan 31;11:43. doi: 10.3389/fimmu.2020.00043. PMID: 32117215; PMCID: PMC7020774
“The CD19 glycoprotein is notoriously difficult to express in a natively folded, soluble form, which limits its utility in diagnosing lymphomas and monitoring CAR-T cell patients. This study presents a successful strategy for producing highly stable, correctly folded recombinant CD19 extracellular domains using mammalian expression systems. The natively folded protein serves as an exceptional tool for evaluating CD19-specific monoclonal antibodies, such as clone B43, and for stimulating CD19-directed CAR-T cells in vitro.”

5. Directed Evolution of Stabilized Monomeric CD19 for Monovalent CAR Interaction Studies and Monitoring of CAR-T Cell Patients
Doerner A, et al.Front Immunol. 2021 May 14;12:674251. doi: 10.3389/fimmu.2021.674251. PMID: 34054881; PMCID: PMC8155657
“Directed evolution remains a powerful methodology to engineer proteins with enhanced biophysical properties, including superior stability and solubility. This research describes the generation of a stabilized, monomeric variant of the CD19 extracellular domain optimized for monovalent interaction studies. This engineered CD19 platform enables high-resolution kinetic screening of therapeutic anti-CD19 antibodies and provides a robust tool for monitoring circulating CAR-T cells in patients.”

For more technical references or data sheets regarding the Anti-human CD19 Monoclonal Antibody (Clone: B43) formats, please contact our scientific support team at message@sydlabs.com.

Syd Labs provides the following in vivo grade recombinant anti-mouse CD19 monoclonal antibodies:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3)

Syd Labs provides the following in vivo grade recombinant anti-human CD19 monoclonal antibodies:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1)
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43)
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63)

Syd Labs provides the following recombinant anti-mouse CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-mouse CD19 monoclonal antibody (Clone: 1D3) for flow cytometry

Syd Labs provides the following recombinant anti-human CD19 monoclonal antibodies for flow cytometry:
Recombinant Anti-human CD19 monoclonal antibody (Clone: SJ25C1) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: FMC63) for flow cytometry
Recombinant Anti-human CD19 monoclonal antibody (Clone: B43) for flow cytometry

Anti-human CD19 (B43) from: Anti-human CD19 Monoclonal Antibody (Clone: B43): PA007272.m2a Syd Labs